Advertisement

Topics

Intercell AG Company Profile

23:15 EST 24th November 2017 | BioPortfolio

Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis undergoing Phase III clinical trials, a vaccine for Hepatitis C in Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

Location

Campus Vienna Biocenter 6
Vienna
1030
Austria

Contact

Phone: 43 1 20 620 0
Fax: 43 1 20 620 300
Email: info@intercell.com


News Articles [0 Results]

None

Drugs and Medications [0 Results]

None

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Multilayer Optimization of Heterogeneous Networks Using Grammatical Genetic Programming.

Heterogeneous cellular networks are composed of macro cells (MCs) and small cells (SCs) in which all cells occupy the same bandwidth. Provision has been made under the third generation partnership pro...

Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa.

H56/AERAS-456+IC31 (H56), composed of two early secretion proteins, Ag85B and ESAT-6, and a latency associated protein, Rv2660, and the IC31 Intercell adjuvant, is a new fusion subunit vaccine candida...

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Intercell AG

Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantia...

Pelias

Founded in October 2005, Pelias combines unique know-how and dedicated development expertise in the field of infectious diseases with advanced projects licensed from Chiron and Intercell. On the basis...

More Information about "Intercell AG" on BioPortfolio

We have published hundreds of Intercell AG news stories on BioPortfolio along with dozens of Intercell AG Clinical Trials and PubMed Articles about Intercell AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intercell AG Companies in our database. You can also find out about relevant Intercell AG Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record